Novavax's (NVAX) vaccine for respiratory syncytial virus (RSV), which causes respiratory...
Mar 18 2013, 08:49 ET
Novavax's (NVAX) vaccine for respiratory syncytial virus (RSV), which causes respiratory tract infections, produced encouraging results in preclinical studies, inducing anti-RSV antibodies in vitro and cutting infectious RSV in a cotton rat challenge model. In clinical and preclinical studies, antibodies were generated at concentrations "significantly above that found to be protective in both humans and cottons rats." The vaccine is in Phase I and Phase II trials. (PR)